Immatics N.V. (IMTX) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Immatics N.V. (IMTX) over the past year, gaining 33.0% versus a loss of 43.4%. Over five years, IMTX leads with a -48.6% price change compared with -77.8% for SLDB. Immatics N.V. is the larger company by market cap ($878.6 million vs $697.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | SLDB |
|---|---|---|
| Share price | $5.77 | $6.25 |
| Market cap | $878.58M | $697.57M |
| 1-day change | -3.03% | -2.95% |
| YTD return | -45.05% | +10.82% |
| 1-year return | -43.43% | +32.98% |
| 5-year return | -48.57% | -77.78% |
| EPS (TTM) | $-1.95 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-174.32M |
| 52-week high | $12.41 | $11.45 |
| 52-week low | $5.72 | $4.65 |
| Distance from 52-week high | -53.51% | -45.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.78% | +199.36% |
| Average volume | 962.74K | 1.30M |
| Shares outstanding | 152.27M | 111.61M |
| Employees | 721 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed IMTX by 76.4 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
IMTX vs SLDB FAQ
Which is bigger, Immatics N.V. or Solid Biosciences?
Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $697.57M for Solid Biosciences (SLDB).
Which stock has performed better over the past year, IMTX or SLDB?
SLDB returned +32.98% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.